Med-Fine Capital is a Shanghai-based venture capital firm specializing in early-stage healthcare and life sciences investments across China. The firm combines scientific expertise with institutional capital to support high-potential companies developing breakthrough medical technologies. With a portfolio of over 60 companies, Med-Fine plays a leading role in China’s biotech and digital health innovation ecosystem.
Med-Fine Capital focuses exclusively on the healthcare sector, including:
The firm invests at the early stage, aiming to discover and support high-value innovations at the frontier of medical science and clinical application. Med-Fine’s investments are grounded in deep scientific diligence and long-term commitment to advancing patient outcomes.
In June 2025, Med-Fine Capital closed its second USD-denominated fund, with participation from a diverse group of limited partners including global fund-of-funds, Hong Kong financial institutions, Singaporean family offices, and strategic corporates from the healthcare industry.
The fund will continue Med-Fine’s strategy of backing early-stage biotech and healthcare startups with disruptive potential. With this new vehicle, the firm plans to deepen its commitment to next-generation medical innovation, focusing on early-stage companies with breakthrough science, regulatory viability, and global commercialization potential.
Leadership
Med-Fine Capital is led by Managing Partner Jack Zhou and Dr. Vince Deng, Partner and Head of Biotech Investment. The leadership team brings a mix of investment, scientific, and operational expertise, with a focus on identifying and nurturing early-stage innovation in the healthcare sector. Dr. Deng’s background in biotech provides the fund with strong domain depth in life sciences and translational medicine.
Investment Strategy
Med-Fine Capital follows a value-discovery approach, identifying novel healthcare technologies with strong scientific validation and long-term differentiation.
The firm provides capital, strategic guidance, and ecosystem access, including partnerships with hospitals, research institutions, and industry experts.
Its multi-currency structure (RMB and USD) enables it to support companies with both domestic and international growth paths.
Med-Fine emphasizes clinical relevance, IP defensibility, and scalable business models in its investment selection.
Notable Investments
Med-Fine’s portfolio includes biotech and medtech innovators such as:
These companies operate across biologics, oncology, gene therapies, digital therapeutics, and specialized healthcare services.
Notable Exits
Specific exits have not been disclosed, but several portfolio companies are known to be progressing through late-stage clinical development or commercialization phases.
Other
Med-Fine Capital offers strategic advantages to healthcare startups, including domain-specific expertise, connections with top-tier research institutions, and a multi-currency fund structure that supports international expansion.
Founders in life sciences and healthtech seeking both scientific validation and long-term capital alignment may find Med-Fine to be a highly suitable partner.
China
